https://doi.org/10.55788/ad88041d
The CONVINCE trial (NTR7138) was a multinational, open-label, randomised-controlled clinical trial that assessed the survival of patients with kidney failure at 30 months following high-dose haemodiafiltration compared with high-flux haemodialysis. Inclusion criteria for CONVINCE included renal replacement therapy (RRT) for more than 2.5 years. The study consisted of 677 patients receiving haemodialysis and 683 patients receiving haemodiafiltration. In the trial, haemodiafiltration showed a reduced risk of death compared with haemodialysis (HR 0.77; 95% CI 0.65–0.93) [1].
A further important consideration when comparing treatments is patients’ feelings of well-being, both physically and emotionally. The presented study aimed to assess PROs in the CONVINCE cohort, using the Patient-Reported Outcome Measurement Information System (PROMIS) [2]. PROMIS examines 8 domains: social participation, depression, anxiety, cognitive function, physical function, pain interference, sleep disturbance, and fatigue. PRO assessments were collected for 84% of the participants. Assessments were taken before randomisation, and then every 3 months for 3 years. This amounted to 10,681 total analysable questionnaires. The omnibus test was used to determine significance.
Overall, all domains of PROMIS revealed a significant deterioration of health throughout the study. The domains with the lowest scores were physical function with a mean T-score ± SD of 44.0 ± 9.9, sleep (49.0 ± 9.3), and anxiety (49.4 ± 9.3). Differences between the haemodiafiltration and haemodialysis groups will be reported in an upcoming paper.
- Blankestijn PJ, et al. N Engl J Med 2023; Aug 24. DOI: 10.1056/nejmoa2304820
- Rose M, et al. Patient-Reported Health Status of Adults with Kidney Failure Receiving Hemodiafiltration vs. Hemodialysis: Results from the CONVINCE Randomized Controlled Clinical Trial. TH-PO1134, ASN Kidney Week 2023, 2–5 November, Philadelphia, PA, USA.
Copyright ©️2023 Medicom Medical Publishers
Posted on
Previous Article
« Donor stem cells may reduce lifelong immunosuppressant use following transplant surgery Next Article
Patient care technicians improve haemodialysis patient outcomes »
« Donor stem cells may reduce lifelong immunosuppressant use following transplant surgery Next Article
Patient care technicians improve haemodialysis patient outcomes »
Table of Contents: ASN 2023
Featured articles
Patient care technicians improve haemodialysis patient outcomes
Sparsentan outperforms irbesartan for treatment of IgAN
Chronic Kidney Disease
Aldosterone synthase inhibition reduces albuminuria in CKD
Low doses of zibotentan with dapagliflozin improve albuminuria in patients with CKD
Spironolactone failed to reduce major adverse cardiac effects in patients with CKD on haemodialysis
Efficacy of bardoxolone methyl for DKD, without increased cardiac risk
Renal Replacement Therapy
New approaches to successful vascular access
Patient care technicians improve haemodialysis patient outcomes
Donor stem cells may reduce lifelong immunosuppressant use following transplant surgery
A systems approach to kidney transplantation disappoints
Glomerular Disease
Obinutuzumab attenuates kidney decline in lupus nephritis
Clinical benefits of sparsentan for patients with FSGS
Sparsentan outperforms irbesartan for treatment of IgAN
Rare or Genetic Kidney Disease
Small molecule PGE1 shows promise for nephronophthisis treatment in vitro and in vivo
Related Articles
September 6, 2021
Chronic kidney disease definition likely inflates disease burden
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com